Physician Views snap poll – Asking rheumatologists five critical questions about AbbVie's Rinvoq

Approved by the FDA in August for the treatment of moderate-to-severely active rheumatoid arthritis (RA), the JAK inhibitor Rinvoq is one of the most important products in AbbVie's portfolio.

The company thinks global sales of Rinvoq, spanning multiple indications including RA, psoriatic arthritis, Crohn's disease, ulcerative colitis and atopic dermatitis, can reach $6.5 billion by 2025. Key opinion leaders believe it could emerge as a best-in-class JAK inhibitor, supported by AbbVie's recognised status as a leader in the immunology and inflammation market.

US Rinvoq sales in the third quarter were on track with consensus expectations at $14 million. Fourth-quarter results, reported in January, will provide further clarification if Rinvoq is delivering against early expectations; in the meantime we are snap-polling US rheumatologists to gauge opinion towards and utilisation of the drug…

________

Q. Have you prescribed Rinvoq (upadacitinib) extended-release tablets for the treatment of moderate-to-severe active rheumatoid arthritis?

Yes – very impressed

Yes – moderately impressed

Yes – not impressed

No, but I intend to in the near future

No

________

Q. How do you perceive the severity of Rinvoq's black-box warning versus other drugs in the JAK inhibitor class: Xeljanz (tofacitinib) and Olumiant (baricitinib)?

Rinvoq’s label is more favourable

The labels are comparable

Rinvoq’s label is less favourable

Don’t know

________

Q. To what extent have safety concerns related to Rinvoq's mechanism of action acted to prevent you from prescribing it to date?

Where 1 = none and 5 = significant

________

Q. Do you perceive Rinvoq to be a best-in-class/potentially best-in-class JAK inhibitor for moderate-to-severely active rheumatoid arthritis at this point in time?

Yes

No

Too early to tell

________

Q. The Institute for Clinical and Economic Review (ICER) recently reported that a head-to-head trial comparing Rinvoq to Humira (adalimumab) shows that Rinvoq is "associated with statistically-significant but modestly higher rates of disease remission and improvement in other important outcomes – evidence that provides moderate certainty that Rinvoq…offers a small to substantial net health benefit over Humira."

ICER adds that "economic modelling shows that Rinvoq…plus a conventional DMARD achieves marginally higher quality of life than what is achieved with Humira…plus a DMARD, at similar costs. Based on this comparison with Humira… ICER's value-based price benchmark range for Rinvoq…is between $44,000 and $45,000. This benchmark represents a 25-26% discount off of Rinvoq's… annual list price of $59,860, a suggested discount that is consistent with the rebates we assume the manufacturer is currently offering."

Will these findings from ICER have any impact on your use/planned use of Rinvoq?

Where 1 = Negative impact, 3 = Neutral impact and 5 = Positive impact

________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.